Zhejiang Hisun Pharmaceutical Co Ltd: A Snapshot of Recent Performance and Operations
Zhejiang Hisun Pharmaceutical Co., Ltd., a prominent player in the health care sector, has been making significant strides in the pharmaceutical industry. Based in Taizhou, China, the company is listed on the Shanghai Stock Exchange and has been operational since its founding in 2000. It went public on July 5, 2000, marking the beginning of its journey in the public market.
As of June 17, 2025, the company’s close price stood at 9.43 CNY. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 10.35 CNY on June 11, 2025, and a low of 6.76 CNY on July 8, 2024. The market capitalization of Zhejiang Hisun Pharmaceutical is currently valued at 11,293,148,251 CNY, reflecting its substantial presence in the market.
The company’s financial metrics indicate a price-to-earnings ratio of 20.0398, suggesting investor confidence in its growth potential. Zhejiang Hisun Pharmaceutical is renowned for its diverse range of pharmaceutical products, including anticancer drugs, cardiovascular medicines, anti-parasitics, and anti-infective products. In addition to its product offerings, the company provides related pharmaceutical solution services, catering to a broad spectrum of healthcare needs.
For more detailed information about Zhejiang Hisun Pharmaceutical and its comprehensive range of products and services, interested parties can visit the company’s website at www.hisunpharm.com .